
- European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume of 4.85 million shares, closed regular trading session at $150.87.
- Medicines and Healthcare products Regulatory Agency (MHRA) has granted UK marketing authorization for Global Blood Therapeutics’ (NASDAQ:GBT) Oxbryta (voxelotor) for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older. Global Blood Therapeutics shares traded in a range of $32.43 to $34.03 on a day volume of 808.38 thousand shares, closed regular trading session at $33.35.